Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study
The results suggest that in aNSCLC patients receiving 1L treatment, US data have the potential to be used in technology evaluations to understand long-term OS where UK data are unavailable or sparse.
Authors
- Philani Mpofu (ORCID: https://orcid.org/0000-0002-6474-029X)
- Jane Adam (ORCID: https://orcid.org/0009-0005-6660-8144)
- Páll Jónsson (ORCID: https://orcid.org/0000-0002-1222-5704)
- Arun Sujenthiran
- Trevor J. Royce (ORCID: https://orcid.org/0000-0001-9879-1290)
- Jyotsna Kasturi
- Brennan Beal (ORCID: https://orcid.org/0000-0001-7748-745X)
- Blythe J. S. Adamson (ORCID: https://orcid.org/0000-0003-4251-2912)
- Stephen Duffield (ORCID: https://orcid.org/0000-0001-9906-1142)
- Seamus Kent
Institutions
- University of Washington (US)
- National Institute for Health and Care Excellence (GB)
- Flatiron Health (United States) (US)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-085722
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Flatiron Health